Drug Trial Radar · NCT06698250
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 18, 2024
Primary completion
Dec 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Anwaar SaeedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Exelixis
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
Conditions
- Hepatocellular Carcinoma
Interventions
ZanzalintinibDrug
Next generation tyrosine kinase inhibitor (TKI) with the target inhibition profile identical to cabozantinib but with a superior pharmacokinetic profile.
DurvalumabDrug
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
TremelimumabDrug
Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 dose (RP2D) of XL-092 with Durvalumab plus TremelimumabTime frame: Up to 12 months
- Objective Response Rate (ORR) (im RECIST)Time frame: Up to 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.